Galapagos NV stock is up 3.68% since 30 days ago. The next earnings date is Nov 2, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 78.57% of the previous 13 December’s closed higher than November.
Galapagos NV engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG.